Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.372 EUR | -5.57% | +42.55% | -1.33% |
Apr. 29 | CLARIANE : Expecting a smaller dilution effect | |
Apr. 26 | CLARIANE : Reiterated outlook backed by a buoyant Q1 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 16.75 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.33% | 287M | B+ | ||
+14.10% | 81.68B | C+ | ||
-30.15% | 69.23B | B- | ||
+9.37% | 29.08B | C+ | ||
-11.90% | 16.88B | B | ||
0.00% | 16.85B | A- | ||
-1.12% | 15.15B | A- | ||
+4.87% | 12.62B | A- | ||
+35.78% | 12.47B | B- | ||
-30.70% | 11.89B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLARI Stock
- Ratings Clariane SE